62-year-old Jacky Cheung was diagnosed, and the concert was canceled! What is this virus? The world's pharmaceutical giants are all eyeing it

National Business Daily

2024-06-08 08:32Published on the official account of Sichuan Daily Economic News

Edited by: Du Yu

According to Zhejiang Online on June 7, "United Daily News" and other Taiwanese media reported on June 7 that 62-year-old "God of Song" Jacky Cheung was originally scheduled to hold the fourth "60+" tour at Taipei Arena on the evening of the 7th, but the organizer confirmed that he was unwell and the concert was suspended.

Jacky Cheung also said through Universal Music's official social account that he was infected with RSV (respiratory syncytial virus) and could not speak normally, so he was sure that he would not be able to perform.

Jacky Cheung said: "I'm very sorry, I started to feel unwell after returning to Hong Kong from the performance last week, and I saw a doctor and confirmed that I was infected with RSV (respiratory syncytial virus), which is generally a virus that children can infect, probably because I am 60+, and they all say that when I get older, I will slowly become a child again, so I was infected." ”

"I always hope that there will be a miracle, and when I wake up, I can go to the venue to rehearse as usual, and perform as usual in the evening, but ...... The miracle did not appear. Jacky Cheung said, "My throat is still sore, and I can't speak normally, in addition, it is a runny nose, nasal congestion, etc., general cold symptoms, you don't have to worry about my health." ”

Jacky Cheung reluctantly announced: "I am sure that I will not be able to perform, disappointing the audience who bought tickets to enter, and I apologize for the trouble caused to the organizers, and I also want to say sorry to everyone, I hope to recover as soon as possible and return to the stage to perform for everyone." I wish you all good health! ”

The organizer of the performance also issued a statement saying: "Because Mr. Jacky Cheung was diagnosed by a doctor with a respiratory infection, the doctor ordered him to take necessary recuperation, and we are deeply sorry for the inconvenience caused to fans and friends who have purchased tickets for the June 7th, 8th, and 9th shows, and propose a refund and related compensation plan at 19:30 on the evening of June 7."

Previously, on March 7, Jacky Cheung canceled three concerts held at the Shanghai Oriental Sports Center on March 8, 9 and 10 due to physical reasons.

According to public information, Jacky Cheung was born in Hong Kong on July 10, 1961, a Chinese pop male singer, film and television actor, and composer, who is loved by many fans.

After the performance market recovered last year, Jacky Cheung held concerts in various places, which was also a physical challenge for him who was over 60 years old. According to media reports, according to incomplete statistics, since June 9, 2023, starting from Macau, in the past 9 months, the "Jacky Cheung 60+ Concert Tour" has held more than 100 concerts in different countries and regions, and on average, one will be held in less than 3 days.

Image source: Fan Bai Tian took a photo on the spot

What is respiratory syncytial virus?

Syncytial virus is respiratory syncytial virus, which is an RNA virus of the pneumoviridae family and the genus Pneumovirusidae. RSV can be infected in people of all ages, but the high-risk groups for RSV infection are mainly concentrated in children, the elderly, and immunocompromised people.

At present, there is no respiratory syncytial virus vaccine and specific treatment drugs on the market. RSV can be reinfected and can easily spread in the home, so in the absence of a vaccine or effective drug, infection should be prevented by strengthening personal protection.

The world's pharmaceutical giants are all eyeing it

On May 31, local time, Moderna, an American vaccine company, announced that its mRNA respiratory syncytial virus (RSV) vaccine (mRESVIA) was approved by the U.S. Food and Drug Administration (FDA). This is the world's second commercial mRNA vaccine after the COVID vaccine, and the world's first non-COVID mRNA vaccine.

On June 3, the Center for Drug Evaluation of the National Medical Products Administration (NMPA) publicly revealed that Pfizer had submitted an application for clinical trials of its respiratory syncytial virus (RSV) vaccine to the center, which was accepted on June 1.

The U.S. Food and Drug Administration (FDA) expanded its approval for GSK's respiratory syncytial virus (RSV) vaccine on June 7 to include adults aged 50 to 59 who are at higher risk of exacerbations after infection with the virus.

The vaccine, called Arexvy, is the first vaccine approved by the FDA to protect this population from RSV. The agency initially approved GSK's vaccine in May 2023 for patients aged 60 and over who are more susceptible to severe cases of the virus.

According to the Centers for Disease Control and Prevention, RSV causes thousands of hospitalizations and deaths in older adults each year. But the virus can also cause serious illness in adults age 50 and older, and even younger, especially those with chronic underlying conditions such as asthma, diabetes and congestive heart failure.

Many domestic pharmaceutical companies are also deploying RSV vaccines, and judging from public information, most of them are in the early stage of research and development, and they are not based on mRNA technology. AVIC Securities Research Report pointed out that at present, the RSV vaccine market is still in the initial stage of rapid opening. In addition to protective efficacy, broad-spectrum protection, continuous vaccination capacity, and safety are the main differentiating competitive indicators of RSV vaccines.

Advexin's RSV vaccine (project number ADV110) is a recombinant protein subunit vaccine for RSV and is in Phase II study. In October 2023, the company said that the team published a research paper on the Phase 2 clinical data of ADV110 on the medical preprint platform medRxiv, presenting data from the Phase 2 clinical trial study that had been obtained through the interim analysis. Safety data showed that different doses of ADV110 vaccine were well safe and well tolerated. Immunogenicity data showed that ADV110 immunization could induce high levels of antibodies in the body, showing a good immunogenicity and dose-response relationship.

Clover Bio (2197. HK) SCB-1019 is a bivalent RSV PreF-trimer subunit vaccine candidate and is currently in Phase 1 clinical trials. In April, Clover said it had positive preliminary immunogenicity and safety data from the first cohort of young adults in a Phase I clinical trial evaluating SCB-1019.

Zhifei Biotech, which has joined hands with GlaxoSmithKline, has laid out the field of RSV adult vaccines, but there is not much relevant information. According to the 2023 financial report, the vaccine is in the preclinical research stage and is expected to be declared for clinical trials from 2024 to 2025.

Walvax Biotech (300142), a leading private vaccine company in China, has obtained the RSV vaccine pipeline through cooperation with Shanghai Blue Magpie Biotech, an mRNA technology company. Walvax's 2022 annual report shows that the advancement of the company's mRNA vaccine technology platform has been verified in a number of mRNA vaccines, and the company and its partners have jointly developed mRNA RSV vaccines, all of which are currently being promoted. In the 2023 financial report, Walvax did not mention the latest progress of RSV vaccines, only saying that in the next 5-10 years, it will strive to gradually achieve the launch of RSV vaccines and other products.

The daily economic news synthesizes Zhejiang online and public information

National Business Daily

View original image 248K

• 

•